AFP
Pharmaceuticals, Biotechnology & Life Sciences
Aft Pharmaceuticals
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 6 Aug 2021
- Reported shorts
- 667
- Shares on issue
- 104.679M
Aft Pharmaceuticals (AFP) financials
Results, ratios and statements
Latest result
Year to 31 Mar 2026 (FY26) vs FY25, figures in NZD, the reporting currency
- Revenue
- 251.2Mvs 205.5M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- NPAT
- 14.7Mvs 12.0M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- EPS (diluted)
- 0.14T (source: Derived: trailing 12 months at year end)vs 0.11 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- +22.2%FY
- EPS YoY
- +27.3%TTM
- Derived: trailing 12 months at year end
Key ratios
Year to 31 Mar 2026 (FY); balance sheet at 31 Mar 2026; prices to 14 Oct 2026
- Gross margin
- 42.6%
- Operating margin
- 6.9%
- Net margin
- 5.9%
- FCF margin
- −7.7%
- ROE
- 14.2%
- ROA
- 7.6%
- FCF conversion
- −1.31×
- Net debt (excl. leases)
- NZD 40.3M
- Net debt / EBITDA
- 1.5×
- Current ratio
- 2.2×
- Interest cover
- 7.8×
- Cash dividends paid / net profit
- 12.8%
- Market cap
- $382.8M
- P/E
- n/a (reports in NZD)
- P/B
- n/a (reports in NZD)
Ratios use the reporting currency (NZD); market cap is in AUD. Source: Yahoo Finance, as at 14 Oct 2026.
Financial statements
Figures in NZD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | 251.2M | 205.5M | 194.0M | 155.8M |
| Gross profit | 107.0M | 89.2M | 86.9M | 72.2M |
| Operating income | 17.2M | 11.7M | 20.3M | 17.1M |
| EBITDA | 27.8M | 21.2M | 27.4M | 20.2M |
| EBIT | 24.1M | 18.6M | 25.4M | 18.4M |
| Interest expense | 2.2M | 2.5M | 3.4M | 2.6M |
| Pretax income | 21.9M | 16.0M | 22.0M | 15.8M |
| Tax | 7.8M | 4.6M | 6.4M | 5.1M |
| NPAT | 14.7M | 12.0M | 15.6M | 10.7M |
| Net interest income | −2.6M | −1.6M | −2.2M | −3.9M |
| EPS basic | 0.14T (source: Derived: trailing 12 months at year end) | 0.11 | 0.15 | 0.10 |
| EPS diluted | 0.14T (source: Derived: trailing 12 months at year end) | 0.11 | 0.15 | 0.10 |
| Shares | 104.9M | 104.9M | 104.9M | 104.9M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- FY26 Annual ReportAnnual Report21 May 2026via asx_announcements
- FY25 Results PresentationOpens in new windowFinancial Report31 Dec 2025via smart_crawler
- FY25H1 Results Appendix 2Opens in new windowFinancial Report31 Dec 2025via smart_crawler
- FY25H1 Results PresentationOpens in new windowFinancial Report31 Dec 2025via smart_crawler
- FY25H1 Interim ReportOpens in new windowFinancial Report31 Dec 2025via smart_crawler
- FY25 Results AnnouncementOpens in new windowFinancial Report31 Dec 2025via smart_crawler
- FY25H1 Results AnnouncementOpens in new windowFinancial Report31 Dec 2025via smart_crawler
- Annual Report - FY2025Opens in new windowAnnual Report31 Dec 2025via smart_crawler
- FY25 Modern Slavery StatementOpens in new windowFinancial Report31 Dec 2025via smart_crawler
- FY25 Market ReleaseOpens in new windowFinancial Report31 Dec 2025via smart_crawler
Showing 10 of 67 reports